Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Average Rating of “Moderate Buy” by Brokerages

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has received an average rating of “Moderate Buy” from the twenty-six research firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have given a buy rating and three have issued a strong buy rating on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $945.32.

Several research analysts have weighed in on REGN shares. BMO Capital Markets lowered their target price on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating for the company in a research note on Tuesday, February 4th. The Goldman Sachs Group lowered their target price on shares of Regeneron Pharmaceuticals from $1,019.00 to $917.00 and set a “buy” rating for the company in a research note on Monday, April 14th. Leerink Partnrs raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 5th. Cantor Fitzgerald assumed coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 22nd. They set an “overweight” rating and a $695.00 price target on the stock. Finally, Bank of America reduced their price target on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an “underperform” rating on the stock in a research report on Thursday, April 17th.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several large investors have recently bought and sold shares of REGN. Capital International Investors boosted its stake in Regeneron Pharmaceuticals by 41.6% in the fourth quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company’s stock valued at $3,373,859,000 after acquiring an additional 1,390,534 shares in the last quarter. Norges Bank acquired a new position in Regeneron Pharmaceuticals in the fourth quarter valued at $802,036,000. GAMMA Investing LLC boosted its stake in Regeneron Pharmaceuticals by 89,825.0% in the first quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company’s stock valued at $517,291,000 after acquiring an additional 814,713 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Regeneron Pharmaceuticals by 63.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company’s stock worth $1,485,527,000 after buying an additional 810,144 shares during the period. Finally, Amundi boosted its stake in shares of Regeneron Pharmaceuticals by 45.8% during the fourth quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company’s stock worth $1,138,074,000 after buying an additional 487,489 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 0.5 %

Shares of REGN opened at $602.64 on Wednesday. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a 12-month low of $525.99 and a 12-month high of $1,211.20. The firm has a 50-day moving average price of $637.38 and a 200 day moving average price of $721.91. The firm has a market capitalization of $65.88 billion, a P/E ratio of 15.74, a P/E/G ratio of 2.34 and a beta of 0.44.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. The firm had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. Regeneron Pharmaceuticals’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $11.86 earnings per share. Sell-side analysts forecast that Regeneron Pharmaceuticals will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were paid a $0.88 dividend. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.58%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.